A Study on the Effect of Valeric Acid in Alzheimer's Induced Rats by the Estimation of Aβ 1-42 Biomarker

Blessina Sugandhi Dulla; Bindhu S.; Leena Pramod K.

doi:10.1055/s-0041-1736274

Journal of Health and Allied Sciences NU, Inhaltsverzeichnis

CC BY-NC-ND 4.0 · Journal of Health and Allied Sciences NU 2022; 12(02): 134-138
DOI: 10.1055/s-0041-1736274

Original Article

A Study on the Effect of Valeric Acid in Alzheimer's Induced Rats by the Estimation of Aβ 1-42 Biomarker

Blessina Sugandhi Dulla

¹Department of Anatomy, Yenepoya Medical College, Yenepoya (deemed to be) University, Mangalore, Karnataka, India

,

Bindhu S.

¹Department of Anatomy, Yenepoya Medical College, Yenepoya (deemed to be) University, Mangalore, Karnataka, India

,

Leena Pramod K.

²Department of Forensic Medicine and Toxicology, Yenepoya Medical College, Yenepoya (deemed to be) University, Mangalore, Karnataka, India

› Institutsangaben

Abstract

The effect of valeric acid on the behavior of Alzheimer's disease (AD)-induced rats by aluminum chloride (100 mg/kg body weight) was assessed using elevated plus maze (EPM) and the Hebb Williams maze (HWM). Amyloid β 1–42(Aβ1–42) biomarker was estimated by ELISA. In this study, valeric acid-treated rats were compared with those treated with piracetam (200 mg/kg), rivastigmine (0.5 mg/kg), and the results showed the rats treated with valeric acid had a very less transfer latency of EPM and HWM when compared with other standard drugs. In addition, valeric acid-treated rats showed reduced levels of amyloid β1–42 biomarker in the plasma. Hence, this study found that valeric acid may be suggested as a better drug for Alzheimer's disease.

Keywords

Alzheimer's disease - amyloid β 1–42 - elevated plus maze - Hebb Williams maze - valeric acid

Volltext

Referenzen

References
1 Rahman H, Shaik HA, Madhavi P, Eswaraiah MC. A review: pharmacognostics and pharmacological profiles of Nardastachys jatamansi DC. Elixir Pharmacy 2011; 39: 5017-5020
2 Achliya G, Barabde U, Wadodkar S, Dorlel A. Effect of Bramhi Ghrita, an polyherbal formulation on learning and memory paradigms in experimental animals. Indian J Pharmacol 2004; 36 (03) 159-162
3 Hassan SK, Mandal US, Mondal DK, Jana D. A study on stress, anxiety and depression among caregivers of the patients with dementia in a tertiary care hospital in eastern India. Int J Sci Res 2020; 9 (01) 7-9
4 Veeresham C. Natural products derived from plants as a source of drugs. J Adv Pharm Technol Res 2012; 3 (04) 200-201
5 Hadley S, Petry JJ. Valerian. Am Fam Physician 2003; 67 (08) 1755-1758
6 Eadie MJ. Could valerian have been the first anticonvulsant?. Epilepsia 2004; 45 (11) 1338-1343
7 Krystal AD, Ressler I. The use of valerian in neuropsychiatry. CNS Spectr 2001; 6 (10) 841-847
8 Ortiz JG, Nieves-Natal J, Chavez P. Effects of Valeriana officinalis extracts on [3H]flunitrazepam binding, synaptosomal [3H]GABA uptake, and hippocampal [3H]GABA release. Neurochem Res 1999; 24 (11) 1373-1378
9 Neamati A, Chaman F, Hosseini M, Boskabady MH. The effects of Valeriana officinalis L. hydro-alcoholic extract on depression like behavior in ovalbumin sensitized rats. J Pharm Bioallied Sci 2014; 6 (02) 97-103
10 Luder AS, Parks JK, Frerman F, Parker Jr WD. Inactivation of beef brain alpha-ketoglutarate dehydrogenase complex by valproic acid and valproic acid metabolites. Possible mechanism of anticonvulsant and toxic actions. J Clin Invest 1990; 86 (05) 1574-1581
11 Monti B, Polazzi E, Contestabile A. Biochemical, molecular and epigenetic mechanisms of valproic acid neuroprotection. Curr Mol Pharmacol 2009; 2 (01) 95-109
12 Frumkes TE, Nelson R. Functional role of GABA in cat retina: I. Effects of GABAA agonists. Vis Neurosci 1995; 12 (04) 641-650
13 Ahmad Rather M, Justin Thenmozhi A, Manivasagam T, Dhivya Bharathi M, Essa MM, Guillemin GJ. Neuroprotective role of asiatic acid in aluminium chloride induced rat model of Alzheimer's disease. Front Biosci (Schol Ed). 2018; 10: 262-275
14 Bhattacharjee S, Zhao Y, Hill JM, Percy ME, Lukiw WJ. Aluminum and its potential contribution to Alzheimer's disease (AD). Front Aging Neurosci 2014; 6: 62
15 Exley C. What is the risk of aluminium as a neurotoxin?. Expert Rev Neurother 2014; 14 (06) 589-591
16 Oshima E, Ishihara T, Yokota O. et al. Accelerated tau aggregation, apoptosis and neurological dysfunction caused by chronic oral administration of aluminum in a mouse model of tauopathies. Brain Pathol 2013; 23 (06) 633-644
17 Fessel J. Prevention of Alzheimer's disease by treating mild cognitive impairment with combinations chosen from eight available drugs. Alzheimers Dement (N Y) 2019; 5: 780-788
18 Bailey JA, Ray B, Greig NH, Lahiri DK. Rivastigmine lowers Aβ and increases sAPPα levels, which parallel elevated synaptic markers and metabolic activity in degenerating primary rat neurons. PLoS One 2011; 6 (07) e21954
19 Copanaki E, Chang S, Vlachos A. et al. sAPPalpha antagonizes dendritic degeneration and neuron death triggered by proteasomal stress. Mol Cell Neurosci 2010; 44 (04) 386-393
20 Brewer GJ, Torricelli JR, Evege EK, Price PJ. Optimized survival of hippocampal neurons in B27-supplemented Neurobasal, a new serum-free medium combination. J Neurosci Res 1993; 35 (05) 567-576
21 Charan J, Kantharia ND. How to calculate sample size in animal studies?. J Pharmacol Pharmacother 2013; 4 (04) 303-306
22 Vishwakarma S, Goyal R, Gupta V, Dhar KL. GABAergic effect of valeric acid from Valerianawallichii in amelioration of ICV STZ induced dementia in rats. Rev Bras Farmacogn 2016; 26 (04) 484-489
23 Varma RK, Singh L, Garg VK, Yadav P, Singh VK. Nootropic effect of vigna mungo (l.) hepper seeds extract in scopolamine induced amnesic rats. World J Pharm Sci 2016; 5 (12) 1176-1192
24 Gawel K, Labuz K, Gibula-Bruzda E. et al. Cholinesterase inhibitors, donepezil and rivastigmine, attenuate spatial memory and cognitive flexibility impairment induced by acute ethanol in the Barnes maze task in rats. Naunyn Schmiedebergs Arch Pharmacol 2016; 389 (10) 1059-1071
25 Abramets II, Kuznetsov YV, Evdokimov DV, Zaika TO. Piracetam potentiates neuronal and behavioral effects of ketamine. Res Pharmacol 2019; 5 (02) 49-55
26 Deepa B, Divya B, Kumari NS, Sanjeev G, Rao S. Effect of electron beam radiations on memory in experimental animal models. Drug Invention Today 2012; 4 (09) 444-446
27 Vasudevan M, Parle M. Effect of Anwala churna (Emblica officinalis GAERTN.): an ayurvedic preparation on memory deficit rats. Yakugaku Zasshi 2007; 127 (10) 1701-1707
28 Glenner GG, Wong CW. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 1984; 120 (03) 885-890
29 Lin WT, Chen RC, Lu WW, Liu SH, Yang FY. Protective effects of low-intensity pulsed ultrasound on aluminum-induced cerebral damage in Alzheimer's disease rat model. Sci Rep 2015; 5: 9671
30 Thippeswamy AH, Rafiq M, Viswantha GLS, Kavya KJ, Anturlikar SD, Patki PS. Evaluation of Bacopa monniera for its synergistic activity with rivastigmine in reversing aluminum-induced memory loss and learning deficit in rats. J Acupunct Meridian Stud 2013; 6 (04) 208-213
31 Auti ST, Kulkarni YA. Neuroprotective effect of cardamom oil against aluminum induced neurotoxicity in rats. Front Neurol 2019; 10: 399
32 Matsubara E, Ghiso J, Frangione B. et al. Lipoprotein-free amyloidogenic peptides in plasma are elevated in patients with sporadic Alzheimer's disease and Down's syndrome. Ann Neurol 1999; 45 (04) 537-541
33 Fukumoto H, Tennis M, Locascio JJ, Hyman BT, Growdon JH, Irizarry MC. Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels. Arch Neurol 2003; 60 (07) 958-964
34 Liu HC, Chiu MJ, Lin CH, Yang SY. Stability of Plasma Amyloid-β 1-40, Amyloid-β 1-42, and Total Tau Protein over Repeated Freeze/Thaw Cycles. Dement Geriatr Cogn Disord Extra 2020; 10 (01) 46-55